Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (33)

I-10Christian Siebel

Consensus on doxorubicin dosing in infants and children: pharmacokinetic simulations and Delphi process

Wednesday 10:10-11:40

I-12Erik Sjögren

Bridging physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) analyses in paediatric drug development: A case study based on intravenous esomeprazole

Wednesday 10:10-11:40

I-26

Population Pharmacokinetics of Tacrolimus in Pediatric Patients having undergone kidney, liver or bowel/liver transplantation.

Wednesday 10:10-11:40

I-30Adrien Tessier

Population pharmacokinetics in adults and model-based extrapolation and dose selection in the paediatric DMD population for drug S48168/ARM210

Wednesday 10:10-11:40

I-31

Population pharmacokinetic and exposure-lymphocyte analysis of FTY720 (Fingolimod/Gilenya) in pediatric patients with Multiple Sclerosis

Wednesday 10:10-11:40

I-41Chakradhara Rao Satyanarayana Uppugunduri

Population pharmacokinetic model for individualized busulfan dosing in children: Annexation to the existing vast list of PopPK models for performance evaluation

Wednesday 10:10-11:40

I-43Louvina van der Laan

Pharmacokinetics of intracellular stavudine-triphosphate in children after reduced-dose: can we improve stavudine’s safety profile?

Wednesday 10:10-11:40

I-50Swantje Völler

Use of second-to-second physiological monitoring data for continuous evaluation of pharmacotherapy in preterm infants: an application to the respiratory stimulant doxapram

Wednesday 10:10-11:40

II-01Esther Encinas

Population pharmacokinetic modelling of the antihistamine bilastine in children within the context of a model informed paediatric drug development approach

Wednesday 15:50-17:20

II-02Aline Engbers

Pharmacokinetics of ibuprofen in very preterm infants with patent ductus arteriosus

Wednesday 15:50-17:20

II-05Dzhem Farandzha

Tacrolimus Population Pharmacokinetic Analysis with Pmetrics in Infants after Liver Transplantation – preliminary data.

Wednesday 15:50-17:20

II-17Nicolas Frey

Bridging from Intravenous to Subcutaneous Formulation of Tocilizumab for Optimal Dose Regimens in Systemic Juvenile Idiopathic Arthritis

Wednesday 15:50-17:20

II-33Verena Gotta

Modelling urea clearance in pediatric and young adult patients on chronic hemodialysis

Wednesday 15:50-17:20

II-71Yu Kyong Kim

A Prospective Population Pharmacokinetic Study for Recommendation of Prophylactic Fluconazole Dosage Regimen in Preterm Infants

Wednesday 15:50-17:20

II-76Gilbert Koch

Characterization of postnatal sodium fluctuation in very preterm neonates

Wednesday 15:50-17:20

II-77Catherine Sherwin

Tacrolimus population pharmacokinetics in paediatric kidney transplant patients

Wednesday 15:50-17:20

III-13Belén Pérez Solans

Mechanistic model of the myeloablative effects of treosulfan and busulfan in pediatric patients undergoing bone marrow transplant

Thursday 09:55-11:30

III-20Ryan Beechinor

A population pharmacokinetic study of high dose methotrexate treatment in infants with acute lymphoblastic leukemia: The importance of modeling inter-occasion variability across treatment cycles

Thursday 09:55-11:30

III-22Agathe Béranger

Piperacillin dosing regimen optimization in critically ill children according to different creatinine clearances

Thursday 09:55-11:30

III-33Jantine Brussee

Dose Individualization of CYP3A Substrates in Children: Characterization of Maturation of Intestinal and Hepatic CYP3A Activity in Children to Predict First-pass and Systemic CYP3A-mediated Metabolism

Thursday 09:55-11:30

III-42Pascal Chanu

Pediatric plans optimization of C.E.R.A. (Continuous Erythropoietin Receptor Activator): clinical evidence obtained through a model-based integration of multisource data

Thursday 09:55-11:30

III-49S. Y. Amy Cheung

Challenges and opportunities in the development of medical therapies for paediatric populations and the role of extrapolation

Thursday 09:55-11:30

III-53Francois Combes

Modeling and Simulation Approach of Everolimus PK/PD Toward Completing a Pediatric Development

Thursday 09:55-11:30

III-61Kim Dao

Evaluation of exposure to vancomycin in neonates under existing dosing regimens using a population pharmacokinetic approach

Thursday 09:55-11:30

IV-03

Population pharmacokinetics of Rimeporide in healthy volunteers and children suffering from Duchenne Muscular Dystrophy (DMD)

Thursday 15:10-16:40

IV-11Hyeong-Seok Lim

Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children with Epilepsy

Thursday 15:10-16:40

IV-14Philip Lowe

Ligelizumab Paediatric Investigation Plan: exposure-response analysis in adult chronic spontaneous urticaria with simulation-based design of adolescent dose-finding

Thursday 15:10-16:40

IV-24Anita Mathias

Joint population pharmacokinetic modelling of sofosbuvir and its metabolites (GS-566500, GS-331007) in Hepatitis C Virus (HCV)-infected adolescents receiving sofosbuvir or ledipasvir/sofosbuvir

Thursday 15:10-16:40

IV-46Sean Oosterholt

Implications of a model-based dosing algorithm for tacrolimus in paediatric kidney transplantation

Thursday 15:10-16:40

IV-50- -

Efficacy and toxicity of intravenous salbutamol in children with acute severe asthma: a prospective clinical PKPD study

Thursday 15:10-16:40

IV-56Violeta Balbas-Martinez

Physiologically-Based Pharmacokinetic model for Ciprofloxacin in healthy children and approximation to children with complicated Urinary Tract Infection

Thursday 15:10-16:40

IV-68Theo Reijmers

Population PK Modelling of Treosulfan in Paediatric Allogeneic Transplant Patients

Thursday 15:10-16:40

IV-71Christelle Rodrigues

A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy

Thursday 15:10-16:40